The life sciences industry has made significant strides in digitizing operations across clinical development and commercial engagement. However, many organizations still struggle with fragmented data, manual coordination, and delayed responses, hindering real-time decision-making. Systems of Execution (SoE) offer a transformative solution by enabling real-time orchestration of tasks, detecting risks, triggering outcomes, and optimizing execution across the enterprise. Watch Everest Group experts Durga Ambati, Chunky Satija, and Nisarg Shah as they delved into the concept of SoE, exploring high-value use cases and industry considerations for successful implementation. Learn how SoE platforms can unify data across commercial, medical affairs, and patient services to deliver coordinated, stakeholder-centric engagement, and how they can act as an intelligent execution layer that bridges core systems and AI applications.

Life sciences commercial teams are facing tighter budgets, faster launch cycles, and growing pressure to prove ROI from every investment and engagement. In this high-stakes environment, a new breed of specialist providers is stepping up, reshaping the commercial services landscape with targeted technology, therapeutic-area expertise, modular IP, and AI-enabled innovation designed for speed and precision. Unlike broad-based integrators, these specialists bring targeted solutions built for complexity in areas such as oncology, rare diseases, and specialty care, which is now essential. By blending therapeutic insights with smart tech and agile delivery, they’re helping sales, marketing, and launch teams move faster, make sharper decisions, and unlock value across the commercial value chain. Watch Everest Group experts as they explored how life sciences commercial services specialists are outpacing traditional integrators. As life sciences enterprises evaluate their provider portfolios, this session offered timely insights on how specialists compete – and often outperform – larger integrators on agility, depth, and commercial impact.

Decentralized clinical trials (DCTs) were a boon during the pandemic. Pharmaceutical enterprises capitalized on the opportunity to conduct remote and virtual trials during a time when isolation was critical. However, in 2023, pharmaceutical enterprises are turning their focus to address new challenges such as scale, data security, and site engagement. In this webinar, our experts presented insights on the trends pharmaceutical enterprises should expect this year, along with data from our 2023 DCT Platforms PEAK Matrix® assessment to shed light on both the demand and supply side of this market. Our speakers discussed: How is the DCT technology market evolving and what does adoption look like across therapy areas and geographies? What sourcing criteria should pharmaceutical enterprises consider for evaluating their DCT needs? What are the supply landscape characteristics and their value propositions?